Current status and future perspectives of platelet function‐guided precision antiplatelet therapy for patients with cerebral infarction Authors: Guoliang Zhu, Xiaoling Chen, Xinyi Huang, Quandan Tan, Qing Cao, Yali Yang, Yapeng Lin, Jie Yang Published: 2026 ABSTRACT AbstractCurrent evidence indicates that antiplatelet therapy as a cornerstone for secondary prevention of cerebral infarction. However, ischemic or bleeding events arising from antiplatelet drug resistance or excessive platelet inhibition can diminish its clinical benefit. These challenges have laid the foundation for individualized antiplatelet treatment. Although cytochrome P450 family 2 subfamily C member 19 (CYP2C19) genetic polymorphisms have partially addressed the issue of drug resistance in these patients, they remain insufficient to resolve the high incidence of both ischemic and bleeding events. Platelet function testing (PFT)‐guided antiplatelet therapy has been proven beneficial in patients after percutaneous coronary intervention, yet its efficacy in patients with cerebral infarction remains controversial. Platelet function provides a direct and comprehensive reflection of antiplatelet effects, offering potential not only to overcome drug resistance but also to guide de‐escalation strategies, thereby mitigating the frequent occurrence of both ischemic and bleeding events in cerebral infarction. Overall, the current application of PFT to guide personalized antiplatelet regimens in patients with cerebral infarction is characterized by considerable variability. In light of recent advances in this field, we herein review the current landscape of PFT‐guided individualized antiplatelet therapy in cerebral infarction, with the aim of summarizing existing evidence and offering suggestions for future research.Keywords: cerebral infarction, platelet function tests, platelet aggregation inhibitors, precision medicine BACKGROUND Antiplatelet with aspirin or clopidogrel has become a widely recognized and commonly used treatment for patients with cerebral infarction and transient ischemic attack (TIA). 1 , 2 However, drug resistance rates as high as 23% for aspirin and 27% for clopidogrel can weaken or even nullify the efficacy of antiplatelet therapy, significantly increasing the relative risk of recurrent stroke. 3 , 4 Additionally, excessively low platelet aggregation function (PAF) may elevate the risk of hemorrhage. 5 These factors necessitate cautious management of antiplatelet therapy in cerebral infarction patients to prevent bleeding events. Therefore, personalized treatment tailored to the reactivity of antiplatelet therapy in cerebral infarction patients is crucial for balancing the risks of ischemic and hemorrhagic events, representing a major challenge in current stroke prevention and treatment. In contrast to conventional guideline‐based antiplatelet therapy, which applies a standardized regimen to all patients with similar clinical characteristics, precision antiplatelet therapy aims to tailor the choice, dosage, or duration of antiplatelet agents based on individual biological characteristics—such as genetic polymorphisms or platelet function—to optimize the balance between ischemic and bleeding risks. In previous studies, the reactivity to antiplatelet drugs has been primarily assessed and defined through genetic testing, and PAF testing. 5 Genes associated with aspirin reactivity include platelet Antigen 1 (PLA1)/A2 and prostaglandin‐endoperoxide synthase 2 (PTGS2), though PLA1/A2 has proven ineffective in predicting clinical outcomes for patients with coronary artery disease (CAD). 6 , 7 Cytochrome P450 family 2 subfamily C member 19 (CYP2C19) and ATP binding Cassette subfamily B member 1 (ABCB1) are among the genes linked to clopidogrel reactivity. 8 , 9 The efficacy of personalized antiplatelet therapy guided by CYP2C19 gene polymorphisms has been confirmed in large‐scale, multicenter clinical trials involving patients post‐cerebral infarction or percutaneous coronary intervention (PCI). 10 , 11 However, genotyping alone fails to account for non‐genetic determinants of drug response—such as sex, age, and concomitant medications—that significantly influence antiplatelet efficacy. 5 Compared to genetic testing, PAF testing offers a more direct and comprehensive approach to evaluating antiplatelet drug reactivity by overcoming limitations such as the indirect nature and incomplete coverage of genetic testing. 5 In recent years, platelet function testing (PFT) devices have gradually evolved from laboratory‐based instruments to point‐of‐care systems. The high degree of automation and simplified operating procedures enable clinical staff to perform PFT directly, greatly enhancing clinical feasibility. Moreover, the rapid response time of these tests makes early intervention possible for the prevention and treatment of acute cerebral infarction. The effectiveness of PAF‐guided personalized antiplatelet therapy has been established in the field of coronary heart disease. 12 Of note, most of the supportive evidence for PFT‐guided antiplatelet therapy originates from studies in patients with CAD or those undergoing PCI, where the pathophysiology, antithrombotic strategies, and bleeding–ischemic risk profiles differ substantially from those in cerebrovascular disease. The higher platelet component in myocardial infarction thrombi makes the antiplatelet strategies for myocardial infarction and cerebral infarction different. 13 Additionally, the higher bleeding risk in stroke patients necessitates more cautious selection of dual antiplatelet therapy type and duration. 14 These differences limit direct extrapolation of PFT‐guided therapy results from CAD to cerebral infarction. Therefore, its application in cerebral infarction remains under exploration. This review summarizes the progress of research on PAF in cerebral infarction, aiming to evaluate current limitations and propose future research directions. THROMBOSIS IN STROKE Thrombosis is the primary mechanism underlying non‐cardioembolic cerebral infarction, occurring through platelet activation, aggregation, and fibrin deposition following atherosclerotic plaque rupture. 15 , 16 , 17 Platelet activation involves three key pathways, which also serve as critical drug targets for antiplatelet therapy 17 : (a) Thromboxane A2 (TxA2) and its thromboxane/prostaglandin endoperoxide (TP) receptors, (b) adenosine diphosphate (ADP) and its P2Y1/P2Y12 receptors, (c) Thrombin and its protease‐activated receptors (PARs). In the secondary prevention of cerebral infarction, pathways (a) and (b) are the primary targets of commonly used antiplatelet drugs, leading to the development of classical agents such as aspirin, clopidogrel, and ticagrelor. TxA2 pathway Inhibitors‐Aspirin Aspirin is the most widely used antiplatelet drug, irreversibly inhibits cyclooxygenase‐1 (COX‐1) to block TxA2 biosynthesis, thereby achieving antiplatelet effects 18 (see Figure 1). Despite its efficacy, some patients exhibit persistent high platelet reactivity after aspirin treatment, termed “aspirin resistance.” 19 The causes of aspirin resistance are multifactorial, involving genetic variants, medication adherence, and platelet turnover. 7 , 20 Notably, aspirin resistance increases the relative risk of recurrent ischemic events and may exacerbate stroke severity and infarct volume. 21 , 22 Mechanisms of antiplatelet drugs‐ aspirin, clopidogrel, and ticagrelor in inhibiting platelet aggregation. AA, arachidonic acid; AC, adenylate cyclase; ADP, adenosine diphosphate; cAMP, cyclic adenosine monophosphate COX‐1, Cyclooxygenase‐1; DAG, diacylglycerol; G, G protein; GP, glycoprotein; IP3, inositol trisphosphate; MLCK‐P, phosphorylated myosin light chain kinase; P2Y12, P2Y purinergic receptor 12; P2Y2, P2Y purinergic receptor 2; PKB/AKT, protein kinase B/protein kinase B; PL3K, phosphoinositide 3‐kinase; PLCβ, phospholipase C beta; PKC, protein kinase C; PI3K, Phosphoinositide 3‐kinase; PIP2, phosphatidylinositol 4,5‐bisphosphate; PGG2, prostaglandin G2; PGH2, prostaglandin H2; PGI2, prostacyclin; Rap1b, Ras‐related protein 1b; TXA2, thromboxane A2; VASP, vasodilator‐stimulated phosphoprotein; VASP‐P, phosphorylated vasodilator‐stimulated phosphoprotein. ADP P2Y12 receptor inhibitors Clopidogrel Clopidogrel is a second‐generation thienopyridine ADP P2Y12 receptor antagonist, is commonly used in combination with aspirin as DAPT and has demonstrated significant efficacy 23 (see Figure 1). However, clopidogrel is a prodrug that requires metabolic activation to exert its effects. 24 After intestinal absorption, 90% of clopidogrel is inactivated by hepatic carboxylesterases, while the remaining 10% undergoes two‐step metabolism via cytochrome P450 (CYP450) isoenzymes to form a highly unstable active metabolite. This metabolite irreversibly binds to platelet ADP P2Y12 receptors. 24 Initially, clopidogrel is oxidized using CYP2C19, cytochrome P450 1A2 (CYP1A2), and cytochrome P450 2B6 (CYP2B6) isoenzymes and is then hydrolyzed to its active metabolite using CYP2C19, cytochrome P450 2C9 (CYP2C9), CYP2B6, and cytochrome P450 3A (CYP3A) isoenzymes. 24 , 25 Due to the high prevalence of CYP2C19 loss‐of‐function polymorphisms, clopidogrel resistance is common in stroke patients. 26 In a large‐scale, multicenter randomized controlled trial (RCT) conducted in China, CYP2C19 loss‐of‐function allele carriers accounted for 54.5% of stroke patients. 27 However, only 38.6% of these carriers exhibited high on‐treatment platelet reactivity (HOPR) after 90 days of clopidogrel therapy, and the risk of recurrent stroke was only marginally higher than non‐carriers (5.1% vs. 5.8%). 27 These findings suggest that CYP2C19 genotyping may have limited utility in identifying clopidogrel resistance, necessitating alternative approaches such as PFT. Ticagrelor Ticagrelor is an oral, reversible, non‐thienopyridine cyclopentyltriazolopyrimidine antagonist of the ADP P2Y12 receptor with rapid onset of action. 28 Notably, it does not require hepatic metabolism for platelet inhibition, distinguishing it from clopidogrel by being unaffected by CYP2C19 polymorphisms 28 (see Figure 1). Consequently, the prevalence of ticagrelor resistance is significantly lower than that of clopidogrel (12.5% vs. 29.7%). Studies have shown that ticagrelor benefits patients with clopidogrel resistance, serving as an alternative therapy. 10 However, compared to clopidogrel‐aspirin dual Antiplatelet Therapy (DAPT), ticagrelor‐aspirin DAPT does not reduce the risk of recurrent stroke (odds ratio [OR]: 1.16, 95% confidence interval [CI]: 0.93–1.44) and increases the risk of bleeding (OR: 1.97, 95% CI: 1.21–3.22). 29 This underscores that excessively low PAF is not optimal and highlights the need for personalized antiplatelet therapy guided by comprehensive assessment of bleeding and ischemic risks. Therefore, PFT‐guided precision medicine represents the future direction, and its clinical value warrants further investigation. PAF TESTING METHODS Multiple methods exist for PAF testing, which can be broadly categorized into point‐of‐care assays and laboratory‐based assays. Point‐of‐care assays are more suitable for clinical use due to their convenience and rapid results. Among them, VerifyNow is the most validated in cardiovascular settings, while thromboelastography (TEG) has weaker predictive value in stroke. PL‐12 is an emerging device with low cost and simple operation, and preliminary evidence suggests it may outperform both in predicting stroke recurrence. 30 Laboratory‐based methods like LTA remain valuable for research but are less practical for routine use (see Table 1). Table 1Main characteristics of the most commonly used PFTs for monitoring response to antiplatelet drugs.Test methodsPrincipleAutomatic assessmentTarget agent(s)AdvantagesDrawbacksCommonly used HPR valuesCommonly used LPR valuesLTAPlatelet aggregationNoP2Y12 inhibitors, Aspirin Historical gold standard; Universally applicable to both aspirin and P2Y12 inhibitors Large sample volume; Influenced by low platelet count; Complex sample preparation (specialized personnel required); Time‐consuming; Poor reproducibility P2Y12 inhibitors: 46% MPA (5 µM ADP), 59% MPA (20 µM ADP) 59%; Aspirin: 20% (0.5 mM AA) NAVASPFlow cytometryNoP2Y12 inhibitors, Aspirin Whole‐blood assay; Small sample volume; High specificity Complex sample preparation; Requires flow cytometer and experienced technician; Expensive P2Y12 inhibitors: 50% PRI; Aspirin: 20% P2Y12 inhibitors: 18% PRI;VerifyNowPlatelet aggregationYesP2Y12 inhibitors, Aspirin Whole‐blood assay; Small sample volume; Extremely simple and rapid Good correlation with LTA; Most extensive evidence for prognostic value Influenced by hematocrit/platelet count; High cost and low accessibility in China; Aspirin module only assesses COX‐1 pathway P2Y12 inhibitors:208 PRU; Aspirin: 550 ARU P2Y12 inhibitors: 85 PRUMultiplate impedance aggregometryMultiple electrode aggregometry (electric impedance)PartialP2Y12 inhibitors, Aspirin Whole‐blood assay; Small sample volume; Rapid results Influenced by low platelet count; Requires sample dilution; Hematocrit may interfere with results P2Y12 inhibitors: 46 U; Aspirin: 40 U P2Y12 inhibitors: 18 UTEGPlatelet contribution to clot strengthNoP2Y12 inhibitors, Aspirin Whole‐blood assay; Global hemostasis assessment Requires experienced technicians; Time‐consuming; Costly P2Y12 inhibitors: 47 mm; Aspirin: 50% P2Y12 inhibitors: 31 mm; Aspirin: 30% AspirinWorksEnzyme‐linked immunosorbent assayPartialAspirin Random urine sample; High stability; High specificity Exclusive to aspirin (not applicable to P2Y12 inhibitors); Requires laboratory ELISA equipment and specialized operation; Not point‐of‐care Aspirin: 11dhTxB2 ≥ 1500 pg/mgNAPL‐12Platelet aggregationYesP2Y12 inhibitors, Aspirin Whole‐blood assay; Simple operation; Rapid results; Low cost Efficacy in guiding precision antiplatelet therapy for cerebral infarction patients still needs further clinical studies P2Y12 inhibitors: 35%/55%; Aspirin: 35%/55% NAAbbreviations: 11dhTxB2, 11‐dehydro‐thromboxane B2; AA, arachidonic acid; ADP, adenosine diphosphate; ARU, aspirin reaction units; COX‐1, cyclooxygenase‐1; HPR, high platelet reactivity; LPR, low platelet reactivity; LTA, light transmission aggregometry; MA, maximum amplitude; mg, milligram; MPA, maximal platelet aggregation; NA, not available; pg, picogram; PRI, platelet reactivity index; PRU, P2Y12 reaction units; P2Y, purinergic receptor P2Y, G‐protein coupled; TEG, thromboelastography; VASP, vasodilator‐stimulated phosphoprotein. Main characteristics of the most commonly used PFTs for monitoring response to antiplatelet drugs. Historical gold standard; Universally applicable to both aspirin and P2Y12 inhibitors Large sample volume; Influenced by low platelet count; Complex sample preparation (specialized personnel required); Time‐consuming; Poor reproducibility P2Y12 inhibitors: 46% MPA (5 µM ADP), 59% MPA (20 µM ADP) 59%; Aspirin: 20% (0.5 mM AA) Whole‐blood assay; Small sample volume; High specificity Complex sample preparation; Requires flow cytometer and experienced technician; Expensive P2Y12 inhibitors: 50% PRI; Aspirin: 20% Whole‐blood assay; Small sample volume; Extremely simple and rapid Good correlation with LTA; Most extensive evidence for prognostic value Influenced by hematocrit/platelet count; High cost and low accessibility in China; Aspirin module only assesses COX‐1 pathway P2Y12 inhibitors:208 PRU; Aspirin: 550 ARU Whole‐blood assay; Small sample volume; Rapid results Influenced by low platelet count; Requires sample dilution; Hematocrit may interfere with results P2Y12 inhibitors: 46 U; Aspirin: 40 U Whole‐blood assay; Global hemostasis assessment Requires experienced technicians; Time‐consuming; Costly P2Y12 inhibitors: 47 mm; Aspirin: 50% P2Y12 inhibitors: 31 mm; Aspirin: 30% Random urine sample; High stability; High specificity Exclusive to aspirin (not applicable to P2Y12 inhibitors); Requires laboratory ELISA equipment and specialized operation; Not point‐of‐care Whole‐blood assay; Simple operation; Rapid results; Low cost P2Y12 inhibitors: 35%/55%; Aspirin: 35%/55% Abbreviations: 11dhTxB2, 11‐dehydro‐thromboxane B2; AA, arachidonic acid; ADP, adenosine diphosphate; ARU, aspirin reaction units; COX‐1, cyclooxygenase‐1; HPR, high platelet reactivity; LPR, low platelet reactivity; LTA, light transmission aggregometry; MA, maximum amplitude; mg, milligram; MPA, maximal platelet aggregation; NA, not available; pg, picogram; PRI, platelet reactivity index; PRU, P2Y12 reaction units; P2Y, purinergic receptor P2Y, G‐protein coupled; TEG, thromboelastography; VASP, vasodilator‐stimulated phosphoprotein. Laboratory‐based assays Laboratory‐based assays include light transmission aggregometry (LTA), 31 flow cytometry, 32 and Multiplate. 33 Among these, LTA is regarded as the gold standard for PFT. 31 However, first generation LTA was manual, which requires complex operations and a large volume of blood for platelet‐rich plasma (PRP) preparation, posing significant challenges for its clinical application. 34 Additionally, laboratory‐based assays often require specialized personnel for operation, meaning that standardizing procedures across multiple centers in clinical studies is difficult. 34 This limits their utility in clinical research and calls for automated testing instruments. Point‐of‐care assays Point‐of‐care PAF assays include VerifyNow, 35 TEG, 36 and other analyzers. 37 , 38 VerifyNow is the most widely used PAF analyzer with LTA method but expensive. 5 Compared with VerifyNow, TEG shows poorer predictive efficacy for clinical outcomes in stroke patients. 39 Currently, numerous point‐of‐care PAF analyzers exist, such as PFA‐200, and PL‐12. 37 , 38 , 40 Studies suggest that PL‐12 may outperform VerifyNow and TEG in predicting stroke recurrence in patients with cerebral infarction, though further research is needed to confirm this. 30 The accessibility and cost of these point‐of‐care assays vary greatly across different regions. VerifyNow is widely accessible and well validated in Western countries. Nevertheless, its high cost restricts its large‐scale application in resource‐limited areas, including parts of Asia and Africa. In China, the domestically developed PL‐12 analyzer features low cost and high availability. To date, clinical evidence for PL‐12 is mainly based on Chinese populations, and its performance in Western and other populations remains to be validated. Regional differences in accessibility, cost and supporting evidence should be fully taken into account when selecting PFT methods for routine clinical practice. Overall, in the field of cerebrovascular disease, point‐of‐care assays are undoubtedly more suitable for clinical application than laboratory‐based assays. 5 This is because point‐of‐care assays allow non‐specialized personnel to process blood samples at the patient's bedside immediately, eliminating the interference of sample storage time on PFT results. 41 It is crucial to acknowledge the challenges of PFT. First, converting results between different testing methods is difficult due to their varying principles. Second, clinical evidence for PFT's predictive efficacy in hemorrhagic events remains insufficient. Third, acute cerebral infarction patients require early initiation of effective antiplatelet therapy, whereas PFT for detecting drug resistance must be performed after the medication has achieved stable efficacy, which may take 2–5 h or longer after loading dose. 42 PAF AND CLINICAL OUTCOMES HOPR HOPR is defined as persistently elevated platelet reactivity despite stable antiplatelet therapy, which is detected by PFT. 43 Thresholds for HOPR vary across different PFT methods (see Table 1). Current studies report an HOPR incidence of 23% (95% CI: 20%–27%) for aspirin and 27% (95% CI: 22%–32%) for clopidogrel. Ethnic disparities exist, with Asians exhibiting higher platelet reactivity. 44 , 45 While some studies equate HOPR with antiplatelet drug resistance, 46 , 47 this approach is incomplete. HOPR reflects post‐treatment PAF without considering baseline reactivity. 48 A patient with pre‐treatment hyperreactivity may still be classified as “resistant” if their post‐treatment reactivity remains above the HOPR threshold, even after significant reduction. Conversely, a patient with low baseline reactivity may be misclassified as “non‐resistant” despite treatment failure. Thus, defining resistance solely by HOPR is limited. Clinically, this distinction matters because patients with high baseline reactivity who achieve substantial platelet inhibition—yet remain above the HOPR threshold—may not require therapy escalation, whereas those with low baseline reactivity who show minimal drug effect despite being below the HOPR threshold might benefit from alternative strategies. Thus, incorporating baseline platelet reactivity into clinical decision‐making could improve the precision of treatment adjustments. However, given its clinical utility in predicting outcomes and guiding treatment adjustments, HOPR remains a valuable metric. 48 Mounting evidence links HOPR to adverse outcomes in cerebral infarction. A meta‐analysis of 4989 patients showed that HOPR significantly increases the risk of major ischemic cardiovascular events (MICE) (OR: 2.93, 95% CI: 1.51–3.91) and recurrent ischemic stroke (OR: 2.65, 95% CI: 1.00–7.01) in minor stroke or TIA patients. 49 Additionally, HOPR correlates with higher all‐cause mortality (RR: 2.43, 95% CI: 1.83–3.22) and stroke recurrence (RR: 2.05, 95% CI: 1.43–2.95). 50 Notably, HOPR also elevates the risk of early neurological deterioration (RR: 2.75, 95% CI: 1.76–4.30), 50 suggesting that antiplatelet therapy's neuroprotective effects are diminished in HOPR patients. Overall, HOPR doubles the risk of adverse outcomes, highlighting the potential benefit of intensified antiplatelet strategies in these patients. Low on‐treatment platelet reactivity (LOPR) LOPR refers to excessively suppressed PAF post‐treatment, often associated with bleeding events. 51 , 52 Similar to HOPR, LOPR thresholds vary by PFT method (see Table 1) and commonly occur with prasugrel, ticagrelor, or high‐dose clopidogrel. 5 , 53 The reported LOPR incidence ranges from 11%–27%, 53 and higher rates may exist in East Asian populations 45 , 54 While less studied than HOPR, LOPR warrants attention. Platelet reactivity in stroke patients should be optimized within a therapeutic window rather than maximally inhibited. 5 A prospective study found that LOPR patients had a 2.5‐fold higher risk of bleeding events during 556 ± 207 days of follow‐up (HR: 2.50, 95% CI: 1.44–4.31) 55 In CAD, LOPR is more extensively studied due to frequent prasugrel/ticagrelor use. 5 , 53 , 56 As DAPT becomes more prevalent in stroke prevention 14 , 57 , 58 and ticagrelor shows benefit in CYP2C19 loss‐of‐function carriers, 10 LOPR may emerge as a growing concern in stroke patients. Currently, research on LOPR's impact on bleeding events remains limited. Overall, optimal antiplatelet therapy in cerebral infarction requires maintaining platelet reactivity within a “therapeutic window.” Both HOPR and LOPR compromise treatment efficacy by increasing ischemic or hemorrhagic risks, respectively. Blanket DAPT strategies are insufficient for these patients. Therefore, PFT‐guided personalized therapy offers a promising approach to improve outcomes. 59 However, a critical challenge in translating PFT into clinical practice is the substantial heterogeneity in HOPR and LOPR thresholds across studies and testing platforms. This variability precludes the establishment of universally applicable cutoff values, complicates cross‐study comparisons, and hinders the development of standardized clinical algorithms. To address the heterogeneity of HOPR and LOPR thresholds across different PFT platforms, future efforts should prioritize platform‐specific validation in prospective cohorts, develop bridging studies to enable cross‐platform conversion, establish an international cerebrovascular consensus on standardized testing protocols, and explore machine learning integration to move beyond fixed cutoffs for individualized risk stratification. PAF‐GUIDED PRECISION THERAPY Intensified antiplatelet therapy Personalized and precision antiplatelet therapy has emerged as a key focus in cardiovascular and cerebrovascular medicine in recent years 59 For patients PCI, RCTs have demonstrated the efficacy of PAF‐guided personalized antiplatelet therapy. 60 , 61 However, clinical evidence for platelet function‐guided intensified antiplatelet therapy in cerebral infarction remains insufficient and controversial (see Table 2). Three retrospective cohort studies from China demonstrated that platelet function‐guided modified antiplatelet therapy could reduce the risk of recurrent ischemic events by 33%–57% in stroke patients without increasing bleeding risk. 62 , 63 , 64 In contrast, an observational study from the United Kingdom found that PFT‐guided individualized treatment was associated with an increased risk of both composite events and bleeding in stroke patients. 65 This inconsistency in findings may be attributed to regional and ethnic differences. Furthermore, how to adjust medication in patients with antiplatelet resistance—whether by increasing the original drug dose, adding a new agent, or switching drugs—also warrants attention. Overall, switching drugs rather than increasing the dose or number of agents appears to offer greater benefit to patients. A key source of bias in observational studies is confounding by indication, where patients deemed at higher risk of recurrent ischemia are more likely to receive PFT‐guided therapy intensification. This non‐randomized allocation inherently biases outcomes against the intervention group, complicating direct comparisons with non‐intensified patients. At present, given the inherent confounding factors in observational data, the true efficacy of PFT‐guided antiplatelet therapy in stroke patients remains uncertain. 66 Methodologically, none of the existing observational studies have employed propensity score matching, inverse probability weighting, instrumental variable analysis, or new‐user designs to control for confounding by indication. For future research, we recommend that observational studies routinely apply propensity score matching or new‐user designs to minimize such bias. Ultimately, large‐scale, multicenter RCTs remain the gold standard to validate the true efficacy of PFT‐guided antiplatelet therapy in cerebral infarction. Table 2Characteristics of platelet function‐guided individualized antiplatelet therapy studies in patients with ischemic stroke.StudyCountryCurrent statusStudy populationSample sizeIntervention/exposureControlStudy outcomesStudy designFollow‐up durationStudy resultsDepta and Bhatt [24]United StatesPublishedPatients with ischemic stroke/TIA812Intensification of antiplatelet therapy guided by PFT (increasing drug dosage, adding other antiplatelet agents, or switching to more potent antiplatelet agents)Patients without antiplatelet therapy modificationComposite outcome: all‐cause mortality, bleeding, or ischemic event; Bleeding events (classified by GUSTO)Retrospective cohort study4.6 ± 1.1 yearsThe modified group had a significantly higher composite outcome (HR = 2.24, p = 0.02) and a trend toward increased bleeding events (HR = 3.56, p = 0.05)Yi et al. [62]ChinaPublishedFirst‐ever NC‐IS patients admitted within 72 h of onset324Antiplatelet therapy modification guided by PFT (increasing aspirin dosage, adding clopidogrel, or switching to clopidogrel/cilostazol)Patients without antiplatelet therapy modificationIschemic events (ischemic stroke, TIA, myocardial infarction); Bleeding events (classified by GUSTO)Retrospective, multicenter cohort study4.8 ± 1.7 yearsThe modified group had significantly lower ischemic events (HR = 0.67, p = 0.01); no difference in bleeding eventsZhang et al. [64]ChinaPublishedNC‐IS patients684Antiplatelet therapy modification guided by PFT (dosage increment, decrement, or drug replacement)Patients without antiplatelet therapy modificationIschemic events; Bleeding eventsSingle‐center retrospective cohort study2 yearsIndividual group had lower incidence of ischemic events (HR = 0.433, p = 0.001); no difference in bleeding eventsYan et al. [63]ChinaPublishedMinor stroke or TIA patients (divided into ICAS and non‐ICAS groups)521After DAPT, PFT‐guided selection of MAPT agentsRandom selection of MAPT agents by clinicians or patientsStroke recurrence; Bleeding eventsSingle‐center retrospective cohort studyMean 18.1 monthsPFT‐guided group had lower stroke recurrence rate; both ICAS and non‐ICAS subgroups benefited; no difference in bleeding eventsPATH STROKE AChinaRecruitment CompletedFirst‐ever NC‐IS patients within 1‐3 months of onset, receiving aspirin monotherapy for ≥8 days1224Antiplatelet therapy modification (switching to clopidogrel/ticagrelor) for patients with aspirin resistance after PFTPatients without antiplatelet therapy modificationHigh on‐treatment platelet reactivity at 30 days; Secondary: ischemic events, stroke, and bleeding events at 180 daysProspective, multicenter randomized controlled trial180 daysNot reported yetPATH STROKE CChinaRecruitingPatients within 48 h of a minor NC‐IS or high‐risk TIA, found to be clopidogrel‐resistant via PFT5138Ticagrelor 90 mg bid + aspirin 100 mg qd for days 1–21; ticagrelor 90 mg bid for days 22–90Clopidogrel 75 mg qd + aspirin 100 mg qd for days 1–21; clopidogrel 75 mg qd for days 22–90Stroke; moderate‐to‐severe bleeding events (classified by GUSTO)Prospective, multicenter randomized controlled trial90 daysNot available yetAbbreviations: Bid, twice daily; DAPT, dual antiplatelet therapy; GUSTO, global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries; HPR, high platelet reactivity; HR, hazard ratio; ICAS, intracranial atherosclerosis; MAPT, multiple antiplatelet therapy; NC‐IS, non‐cardioembolic ischemic stroke; PATH STROKE: Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic Stroke; PFT, platelet function testing; qd, once daily; RCT, randomized controlled trail; TIA, transient ischemic attack. Characteristics of platelet function‐guided individualized antiplatelet therapy studies in patients with ischemic stroke. Abbreviations: Bid, twice daily; DAPT, dual antiplatelet therapy; GUSTO, global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries; HPR, high platelet reactivity; HR, hazard ratio; ICAS, intracranial atherosclerosis; MAPT, multiple antiplatelet therapy; NC‐IS, non‐cardioembolic ischemic stroke; PATH STROKE: Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic Stroke; PFT, platelet function testing; qd, once daily; RCT, randomized controlled trail; TIA, transient ischemic attack. Currently, a multicenter RCT (ClinicalTrials.gov ID: NCT06269432) is evaluating the safety and efficacy of PAF‐guided precision antiplatelet therapy in aspirin‐resistant stroke patients, aiming to reduce HOPR and stroke recurrence (see Table 2). This may provide new evidence for PFT‐guided precision therapy. Notably, clopidogrel exhibits higher resistance and HOPR rates than aspirin. 3 , 43 The clinical significance of identifying clopidogrel‐resistant patients is underscored by long‐term follow‐up data. Studies have shown that CYP2C19 loss‐of‐function allele carriers treated with clopidogrel have a significantly increased risk of stroke recurrence over 5 years. 67 This evidence supports the need for intensified or alternative antiplatelet strategies in this population. The CHANCE‐2 trial has validated CYP2C19 genotype‐guided therapy. 10 Beyond CYP2C19, a polygenic risk score incorporating other relevant variants, such as prostaglandin‐endoperoxide synthase 1 (PTGS1) 7 and ABCB1, 68 may enable more comprehensive prediction of drug response. However, its clinical utility in stroke remains to be established. 69 A multicenter RCT (NCT06853535) is exploring whether ticagrelor intensification benefits clopidogrel‐HOPR stroke patients compared to standard clopidogrel therapy. The safety and efficacy of PAF‐guided precision antiplatelet therapy in clopidogrel‐resistant stroke patients remains unproven (see Table 2). Although guidelines recommend DAPT for moderate‐to‐high risk TIA patients as well, post‐hoc analyses of the POINT trial have demonstrated that the risk of recurrent stroke is relatively low in this population. 70 Specifically, the 7‐day recurrence rate was merely 1.5% in high‐risk patients, far below the expected rate of 11.7%. 70 When taking bleeding risk into consideration, the actual clinical benefit of DAPT in such patients raises concerns. Clinically, PFT can identify TIA patients with HOPR, who appear to be the population most likely to benefit from long‐term DAPT for the reduction of recurrent ischemic events. Nevertheless, this hypothesis needs to be verified by further clinical research. In conclusion, PAF‐guided intensified antiplatelet therapy may benefit stroke patients, but robust evidence from high‐quality RCTs is needed. De‐escalated antiplatelet therapy De‐escalation therapy aimed at shortening the duration of DAPT has become a major focus in the management of cardiovascular and cerebrovascular diseases. In CAD, platelet function‐guided antiplatelet de‐escalation has shown non‐inferior outcomes, 12 , 59 but such data are lacking in stroke. However, caution is warranted when extrapolating these findings to stroke patients. Coronary and cerebrovascular territories differ in vascular anatomy, thrombus composition, and the relative balance of ischemic versus bleeding risks. Direct translation of de‐escalation strategies from the coronary domain to secondary stroke prevention remains unsubstantiated. De‐escalation is particularly warranted for stroke patients with LOPR, as it may reduce bleeding and medication burden without compromising efficacy. Recent large‐scale RCTs have confirmed that reducing the duration of DAPT can effectively maintain antiplatelet efficacy while lowering the incidence of bleeding events. 71 Currently, a 21‐day course of DAPT is recommended by guidelines as a secondary prevention strategy for cerebral infarction. A post‐hoc analysis of the CHANCE trial found that the superiority of DAPT over single antiplatelet therapy (SAPT) in reducing the risk of recurrent ischemic stroke was primarily observed within the first week. 72 , 73 Furthermore, a similar trend has been observed in multiple RCTs including POINT, INSPIRES, and THALES. 74 , 75 , 76 The POINT trial has confirmed that shortening the duration of DAPT can reduce the risk of bleeding. 74 Therefore, personalized antiplatelet de‐escalation guided by PFT may hold promise as a superior secondary prevention strategy for cerebral infarction, although this necessitates further investigation. Future stroke‐specific trials should include composite endpoints (ischemic plus bleeding events) along with functional neurological outcomes (e.g., mRS) rather than focusing solely on vascular events, conduct multi‐regional and ethnicity‐stratified trials to validate PFT thresholds across populations, and explore the feasibility and optimal timing of PFT in the acute phase (<72 h). DISCUSSION This review systematically evaluated the current status of platelet function‐guided precision antiplatelet therapy by synthesizing existing literature. Although the potential value of PFT in guiding precision therapy for cerebral infarction is recognized, robust evidence from evidence‐based medicine remains lacking. Challenges in platelet function‐guided precision antiplatelet therapy for stroke should be acknowledged. First, HOPR or LOPR can only be determined after initiating antiplatelet therapy. 77 Since the risk of recurrent stroke declines with time after acute cerebral infarction, 78 patients must undergo standard antiplatelet treatment and PFT before receiving personalized regimens, precluding immediate precision therapy upon admission. In the acute phase, guideline‐recommended standard antiplatelet therapy (e.g., DAPT) should be initiated immediately without waiting for PFT results. PFT should be performed after achieving stable drug effect following the loading dose (2–5 h), and its results should primarily guide subsequent long‐term individualized secondary prevention (e.g., de‐escalation or intensification), rather than initial decision‐making. Second, PFT requires agonists (e.g., arachidonic acid [AA], ADP) determined by the antiplatelet agent. 79 , 80 Converting platelet function results across different agonists remains a challenge, 30 , 81 and no universal agonist currently exists to directly reflect the efficacy of most antiplatelet drugs (aspirin, clopidogrel, ticagrelor). Third, platelet function is influenced by individual medical history, circadian rhythmicity, immune‐inflammatory status, and other factors, 82 , 83 , 84 introducing inconsistency in testing populations and timing. Finally, the East Asian Paradox necessitates race‐specific PFT thresholds for stroke prevention, requiring large clinical studies across diverse regions—a task that significantly increases research workload. Future directions for platelet function‐guided precision therapy in stroke include: First, while a trial (ClinicalTrials.gov ID: NCT06269432) is evaluating PFT‐guided intensified therapy for clopidogrel‐resistant acute stroke, similar research for aspirin‐resistant patients remains absent. Second, the non‐inferiority of de‐escalated therapy for LOPR stroke patients during recommended dual antiplatelet therapy requires investigation. Third, in primary prevention of cardiovascular disease, although aspirin's efficacy remains controversial, 85 , 86 it reduces vascular events in specific populations. However, no study has used PFT to identify individuals who benefit from aspirin prophylaxis, presenting an opportunity for PFT in primary stroke prevention. Finally, platelet function and gene polymorphisms each offer advantages in evaluating drug resistance, 5 , 87 but the value of combining them for precision therapy remains unclear. Beyond combining PFT and genotyping, emerging artificial intelligence approaches offer new opportunities for individualized antiplatelet therapy in cerebral infarction. 88 Machine learning models can integrate multimodal data—including clinical characteristics, genetic variants, platelet function phenotypes, imaging biomarkers (e.g., cerebral microbleeds, white matter hyperintensities), and dynamic laboratory parameters—to predict individual risks of recurrent ischemia and bleeding. Such models may move beyond fixed HOPR/LOPR thresholds by generating continuous, patient‐specific risk estimates, thereby enabling truly personalized decision‐making. Furthermore, reinforcement learning algorithms could be applied to optimize sequential antiplatelet strategies (e.g., when to escalate, de‐escalate, or switch agents) based on real‐time clinical feedback. However, prospective validation in multicenter cohorts and the development of user‐friendly clinical decision support tools are needed before these approaches can be integrated into routine stroke care. CONCLUSION In summary, current studies support the potential of PFT‐guided precision antiplatelet in patients with cerebral infarction. However, high‐quality evidence is still lacking to confirm the efficacy of platelet function‐guided precision therapy. AUTHOR CONTRIBUTIONS Study concept and design: Guoliang Zhu and Jie Yang. Acquisition of data: Guoliang Zhu and Xiaoling Chen. Analysis and interpretation of data: Xinyi Huang, Quandan Tan, Qing Cao, Yali Yang, and Yapeng Lin. Drafting of the manuscript: Guoliang Zhu. Revising it for intellectual content: Jie Yang, Xiaoling Chen, Xinyi Huang, Quandan Tan, Qing Cao, Yali Yang, and Yapeng Lin. Final approval of the completed manuscript: Guoliang Zhu, Xinyi Huang, Quandan Tan, Qing Cao, Yali Yang, Yapeng Lin, and Jie Yang. Agreement to be accountable for all aspects of the work: Guoliang Zhu, Xinyi Huang, Quandan Tan, Qing Cao, Yali Yang, Yapeng Lin, and Jie Yang. CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. As an editorial board member of this journal, Jie Yang abstained from peer review and the final decision‐making for this manuscript. ETHICS STATEMENT The authors have nothing to report. ACKNOWLEDGMENTS The graphical abstract and the figure were created with Biorender. This study was supported by grants from the National Natural Science Foundation of China (No. 82571515), the Key R&D Project of Sichuan Provincial Department of Science and Technology (No. 2023YFS0042), the Science and Technology Project of Sichuan Provincial Health Commission (No. 24LCYJZD04), the Yantu Neuroscience Special Scientific Research Fund Project, the China International Medical Exchange Foundation (No. Z‐2017‐24‐2509), and the Special Project for Scientific Research Cooperation of North Sichuan Medical College (No. CBY25‐ZXZDA05). The funders have no role in the design, data collection, data analysis, interpretation, or writing of this manuscript. Zhu G, Chen X, Huang X, et al. Current status and future perspectives of platelet function‐guided precision antiplatelet therapy for patients with cerebral infarction. Neuroprotection. 2026;1‐12. 10.1002/nep3.70057 42023270 Managing Editor: Ningning Wang DATA AVAILABILITY STATEMENT The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request. REFERENCES Associated Data Data Availability Statement The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.